X4 Pharmaceuticals Stock Total Debt
| XFOR Stock | USD 0.37 0.03 8.82% |
X4 Pharmaceuticals fundamentals help investors to digest information that contributes to X4 Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of XFOR Stock. The fundamental analysis module provides a way to measure X4 Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to X4 Pharmaceuticals stock.
As of 11/22/2024, Total Debt To Capitalization is likely to grow to 0.55. XFOR | Total Debt |
X4 Pharmaceuticals Company Total Debt Analysis
X4 Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current X4 Pharmaceuticals Total Debt | 58.28 M |
Most of X4 Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, X4 Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
XFOR Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for X4 Pharmaceuticals is extremely important. It helps to project a fair market value of XFOR Stock properly, considering its historical fundamentals such as Total Debt. Since X4 Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of X4 Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of X4 Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
XFOR Total Debt Historical Pattern
Today, most investors in X4 Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various X4 Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of X4 Pharmaceuticals total debt as a starting point in their analysis.
X4 Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
XFOR Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, X4 Pharmaceuticals has a Total Debt of 58.28 M. This is 97.88% lower than that of the Biotechnology sector and 82.06% lower than that of the Health Care industry. The total debt for all United States stocks is 98.9% higher than that of the company.
XFOR Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses X4 Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics of similar companies.X4 Pharmaceuticals is currently under evaluation in total debt category among its peers.
X4 Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in X4 Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of X4 Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing X4 Pharmaceuticals' value.| Shares | State Street Corp | 2024-06-30 | 2.8 M | Ensign Peak Advisors Inc | 2024-06-30 | 2.5 M | Sio Capital Management, Llc | 2024-06-30 | 2.5 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Schonfeld Strategic Advisors Llc | 2024-06-30 | 1.3 M | Ubs O'connor Llc | 2024-06-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-06-30 | 806.6 K | Velan Capital Investment Management Lp | 2024-06-30 | 659 K | Point72 Asset Management, L.p. | 2024-06-30 | 543.1 K | Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 16.9 M | Nea Management Company, Llc | 2024-06-30 | 15 M |
XFOR Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | -0.4 | ||||
| Profit Margin | 31.32 % | ||||
| Operating Margin | (60.21) % | ||||
| Current Valuation | 1.28 M | ||||
| Shares Outstanding | 170.55 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 67.66 % | ||||
| Number Of Shares Shorted | 11.42 M | ||||
| Price To Book | 0.97 X | ||||
| Price To Sales | 111.48 X | ||||
| Gross Profit | 3 M | ||||
| EBITDA | (107.1 M) | ||||
| Net Income | (101.17 M) | ||||
| Cash And Equivalents | 47.38 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 58.28 M | ||||
| Debt To Equity | 1.28 % | ||||
| Current Ratio | 2.39 X | ||||
| Book Value Per Share | 0.30 X | ||||
| Cash Flow From Operations | (96.51 M) | ||||
| Short Ratio | 8.64 X | ||||
| Earnings Per Share | (0.07) X | ||||
| Target Price | 2.68 | ||||
| Number Of Employees | 127 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 62.76 M | ||||
| Total Asset | 147.26 M | ||||
| Retained Earnings | (477.9 M) | ||||
| Working Capital | 99.21 M | ||||
| Net Asset | 147.26 M |
About X4 Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with XFOR Stock
Moving against XFOR Stock
| 0.74 | PRAX | Praxis Precision Med | PairCorr |
| 0.71 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.67 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.57 | ALVO | Alvotech | PairCorr |
| 0.52 | AKRO | Akero Therapeutics | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.